In a prospective case control study that enrolled 47 GBM patients with DC vaccine adjuvant therapy, better outcomes were predicted with younger age and a lower programmed cell death protein 1 (PD-1)+/CD8+ ratio in TILs and PBMCs [90]. Here, CD8A is linked to glioblastoma.